Abstract
It was the aim of this study to compare the diagnostic properties of two second generation anti-CCP antibodies assays (Quanta Lite CCP, Inova and EliA CCP, Phadia) with an assay containing a new antigen mixture (Quanta Lite CCP 3, Inova) and RF IgM. METHODS: Sera from 86 RA patients and 90 control patients with other diseases, such as infections, connective tissue diseases, or other rheumatic diseases, were analysed using the four different methods. Specificity (84.4%) and PPV (80.3%) were lowest for RF IgM and highest for EliA CCP (specificity 97.8%, PPV 96.7%), the other values being close to those of EliA CCP. Sensitivity was highest for Quanta Lite CCP (73.3%). Efficiency was highest for Quanta Lite CCP (84.1%) at the lower cut off followed by EliA CCP at both cut offs (83.0%). The discrimination between RA sera (mean value 407.67 U/ml) and control sera (4.54 U/ml) and the relative risk (23.34) were best for EliA CCP. The results of this study reveal that there was no advantage of the anti-CCP antibodies assay applying a new antigen mixture (Quanta Lite CCP 3 ELISA) compared to two second generation anti-CCP antibodies assays (Quanta Lite CCP ELISA and EliA CCP).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nienhuis RL, Mandena E (1964) Ann Rheum Dis 23:202–205
Youinou P, Le Goff P, Maran R (1976) In: Peter JB, Shoenfeld Y (eds), Autoantibodies. Elsevier, Amsterdam, pp 618–623
Youinou P, Le Goff P, Dumay A et al (1990) Clin Exp Rheumatol 8:259–264
Yanmaz Alnigenis MNY, Warikoo S, Barland P (2000) J Rheumatol 27:2056–2057
Young BJJ, Mallya RK, Leslie RDG et al (1979) Br Med J 2:97–99
Sharma BL, Rani R, Misra R et al (2000) Indian J Med Res 111:215–218
Paimela L, Gripenberg M, Kurki P et al (1992) Ann Rheum Dis 51:743–746
Bas S, Perneger TV, Seitz M et al (2002) Rheumatology 41:809–814
Vincent C, de Keyser F, Masson-Bessiere C et al (1999) Ann Rheum Dis 58:42–48
Forslind K, Vincent C, Serre G et al (2000) Scand J Rheumatol 29:320–322
Paimela L, Palosuo T, Aho K et al (2001) Ann Rheum Dis 60:32–35
Schellekens GA, De Jong BA, van den Hoogen FH et al (1998) J Clin Invest 101:273-281
Girbal-Neuhauser E, Durieux J, Arnaud M et al (1999) J Immunol 162:585–594
Schellekens GA, Visser H, de Jong BA et al (2000) Arthritis Rheum 43:155–163
van Gaalen FA, Visser H, Huizinga TW (2005) Ann Rheum Dis 54:1510–1512
van Venrooij WJ, Zendman AJ, Pruijn GJ (2006) Autoimmun Rev 6:37–41
Avouac J, Gossec L, Dougados M (2006) Ann Rheum Dis 65:845–851
Drynda S, Drynda A, Wollenberg H et al (2006) Poster presented at EULAR 2006
Coenen D, Verschueren P, Westhoven R et al (2007) Clin Chem 53:3 (doi:10.137/clinchem.2006.078083)
Abreu I, Cardoso C, Martins T et al (2006) Poster presented at ACR/ARHP Annual Scientific Meeting 2006
Bizzaro N, Villalta D, Tozzoli R et al (2006) Poster presented at ACR/ARHP Annual Scientific Meeting 2006
Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML (2007). Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J Autoimmun 28:55–58
Blank M, Shoenfeld Y (2007) B cell targeted therapy in autoimmunity. J Autoimmun 28:62–68
Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, Blackshear PJ (2006) Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun 26:182–196
Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29:1–9
Gupta B, Raghav SK, Agrawal C, Chaturvedi VP, Das RH, Das HR (2006) Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun 27:125–133
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75
O’Connor KH, Banga JP, Darmanin C, El-Kabbani O, Mackay IR, Rowley MJ (2006) Characterisation of an autoreactive conformational epitope on GAD65 recognised by the human monoclonal antibody b78 using a combination of phage display, in vitro mutagenesis and molecular modelling. J Autoimmun 26:172–181
Ola TO, Biro PA, Hawa MI, Ludvigsson J, Locatelli M, Puglisi MA, Bottazzo GF, Fierabracci A (2006) Importin beta: a novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage. J Autoimmun 26:197–207
Rivadeneyra-Espinoza L, Ruiz-Arguelles A (2006) Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways. J Autoimmun 26:52–56
Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A (2006) Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 26:66–71
Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169
Victora GD, Bilate AM, Socorro-Silva A, Caldas C, Lima RC, Kalil J, Coelho V, Victora CG (2007) Mother-child immunological interactions in early life affect long-term humoral autoreactivity to heat shock protein 60 at age 18 years. J Autoimmun 29:38–43
Youinou P (2007) B cell conducts the lymphocyte orchestra. J Autoimmun 28:143–151
Zlacka D, Vavrincova P, Hien Nguyen TT, Hromadnikova I (2006) Frequency of anti-hsp60, -65 and -70 antibodies in sera of patients with juvenile idiopathic arthritis. J Autoimmun 27:81–88
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Correia, M.L., Carvalho, S., Fortuna, J. et al. Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients. Clinic Rev Allerg Immunol 34, 21–25 (2008). https://doi.org/10.1007/s12016-007-8030-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-007-8030-5